Navigation Links
Malaria immunity trigger found for multiple mosquito species

Researchers at the Johns Hopkins Bloomberg School of Public Health have for the first time identified a molecular pathway that triggers an immune response in multiple mosquito species capable of stopping the development of Plasmodium falciparum-the parasite that causes malaria in humans.

By silencing the gene, caspar, the researchers were able to block the development of the malaria-causing parasite in Anopheles gambiae, A. stephensi and A. albimanus mosquitoes-three mosquito species that spread malaria in Africa, Asia and the Americas. Their findings were published March 13 in PLoS Pathogens.

According to the study, the transcription factor Rel 2 is a key molecule involved in regulating several potent anti-Plasmodium defense genes that attack the parasite in the mosquito gut. Rel 2 is activated by the immune deficiency pathway (Imd) which, in turn, is negatively regulated by the caspar gene; when caspar is silenced the Rel 2 is activated. The researchers found that silencing of the caspar gene through the manipulation of gene expression resulted in mosquitoes that successfully blocked the development of Plasmodium falciparum in the gut tissue. Silencing the gene known as cactus, which is part of another pathway called Toll, was shown to have similar effect in controlling the development of Plasmodium berghei, which causes malaria in rodents.

"When a mosquito is feeding on malaria-infected blood, the parasite will be recognized by the mosquito's immune system through receptors that then start the immune response. In the wild, this response is believed to occur too late to mount an efficient immune defense that would kill all parasites. At least a few Plasmodia will successfully develop inside the mosquito and enable transmission of malaria," explained George Dimopoulos, PhD, senior author of the study and associate professor at the Johns Hopkins Malaria Research Institute.

"In the lab we activated this immune response in advance of infection, giving the mosquito a head start in defeating the invading parasite."

Dimopoulos and his colleagues Lindsey Graver and Yuemei Dong also found that Rel 2 activation did not affect the survival and egg laying fitness of the modified mosquitoes.

"This came as a pleasant surprise since it essentially means that we one day could spread this trait in natural mosquito populations using genetic modification. Furthermore, by activating Rel 2, the genetically modified mosquitoes will attack the malaria parasite with several independent immune factors, and this will make it very difficult for Plasmodium to develop resistance," said Dimopoulos.


Contact: Tim Parsons
Johns Hopkins University Bloomberg School of Public Health

Related biology news :

1. Researchers identify new way the malaria parasite and red blood cells interact
2. Synthetic biology can help extend anti-malaria drug effectiveness
3. Milestone achieved toward production of malaria treatment using synthetic biology and fermentation
4. LSTM and UoL secure £1.4m ($2m) to develop new magic bullet antimalarial drug
5. Malaria parasite zeroes in on molecule to enhance its survival, team finds
6. African thicket rat malaria linked to virulent human form
7. New papers offer insights into process of malarial drug resistance
8. ASU researchers receive NIH awards for studies of malaria and emergent disease
9. Geisinger research: Antimalarial drug prevents diabetes in arthritis patients
10. New way to make malaria medicine also first step in finding new antibiotics
11. NTDs burden in Latin America and the Caribbean may exceed that of HIV/AIDS, TB and malaria
Post Your Comments:
(Date:6/20/2016)... Securus Technologies, a leading provider of ... safety, investigation, corrections and monitoring announced that after ... secured the final acceptance by all three (3) ... Systems (MAS) installed. Furthermore, Securus will have contracts ... by October, 2016. MAS distinguishes between legitimate wireless ...
(Date:6/7/2016)... 7, 2016  Syngrafii Inc. and San Antonio ... that includes integrating Syngrafii,s patented LongPen™ eSignature "Wet" ... collaboration will result in greater convenience for SACU ... while maintaining existing document workflow and compliance requirements. ... Highlights: ...
(Date:6/1/2016)... -- Favorable Government Initiatives Coupled With Implementation ... to Boost Global Biometrics System Market Through 2021  ... " Global Biometrics Market By Type, By End ... - 2021", the global biometrics market is projected to ... growing security concerns across various end use sectors such ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , the ... today the Clinical Reach Virtual Patient Encounter CONSULT module which enables both ... physician and clinical trial team. , Using the CONSULT module, patients and physicians can ...
(Date:6/27/2016)... 27, 2016  Liquid Biotech USA ... of a Sponsored Research Agreement with The University ... (CTCs) from cancer patients.  The funding will be ... correlate with clinical outcomes in cancer patients undergoing ... then be employed to support the design of ...
(Date:6/24/2016)... , June 24, 2016 Epic Sciences ... detects cancers susceptible to PARP inhibitors by targeting ... cells (CTCs). The new test has already been ... in multiple cancer types. Over 230 ... damage response pathways, including PARP, ATM, ATR, DNA-PK ...
(Date:6/23/2016)... ... 23, 2016 , ... Mosio, a leader in clinical research ... Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits the ... tools, and strategies for clinical researchers. , “The landscape of how patients receive ...
Breaking Biology Technology: